Has Amgen Already Won Its BPCIA Dispute With Sandoz?

Authors

Name

Brian D. Coggio

Person title

Of Counsel

By: Ron Vogel and Brian Coggio

Fish attorneys Brian Coggio and Ron Vogel recently published an article in Law360 where they discuss the Supreme Court determination “that Sandoz ‘violated’ the Biologics Price Competition and Innovation Act by failing to disclose its confidential information to Amgen. And according to the court, this violation is "unlawful" under California unfair competition law. Accordingly, has the disclosure issue been resolved?”

To read the full article, visit Law360.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.

Law360: Has Amgen Already Won Its BPCIA Dispute With Sandoz?

Authors

Federal Circuit to Consider the Relevance of an Alleged Infringer’s “Intent” in a Hatch-Waxman Safe Harbor Analysis

Fish Attorneys Author IP Litigator Article, "Regenxbio v. Sarepta: Make Sure You're Safely Within the Safe Harbor Before Using a 'Research Tool'"

REGENXBIO v. SAREPTA: Make Sure You're Safely Within the Safe Harbor Before Using a "Research Tool"

Users of Research Tools Take Note

Attorneys for Branded Companies Should Carefully Review ANDAs for Admissions Regarding Generic Infringement

First Circuit Finds Device Patent Improperly Listed in the Orange Book

Generic Drug Labeling and Induced Patent Infringement

Prodrugs — Federal Circuit Holds That A PTE Does Not Cover Their Metabolites

Potential Ways for Avoiding the Presumption of Prosecution History Estoppel of an Allowable Dependent Claim Depending from a Rejected Independent Claim

Ensnarement Defense To Doctrine of Equivalents Succeeds On Summary Judgment

Hatch-Waxman 101

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

ITC Monthly Wrap-Up: February 2024

ITC Monthly Wrap-Up: January 2024

Texas Patent Litigation Monthly Wrap-Up: December 2023

Hatch-Waxman 2023 Year in Review

Middle District of North Carolina Finds Public Interest Favors Granting Preliminary Injunction

ITC Monthly Wrap-Up: December 2023

The Federal Circuit Weighs in On Hatch-Waxman “Skinny” Label Infringement Dispute

Legal Alert: Biden Administration Proposes March-In Rights Framework for Pharmaceutical Patents in Effort to Lower Drug Prices